Sera Prognostics (SERA) Q3 2026 earnings review
Sera Prognostics wins Florida Medicaid coverage, but unpaid tests limit sales
Sera Prognostics, the maker of the PreTRM blood test for premature birth risk, won a second state Medicaid coverage decision while collected sales stayed tiny. Test volume jumped 54% from last quarter, and Florida added the test to its Medicaid fee schedule alongside Illinois, which set its price at $525. Even so, quarterly revenue reached only $42,000 because chief executive Zhenya Lindgardt's team ran a high share of unpaid or low-priced tests.
| PreTRM test volume | +54% from last quarter (almost 5x Q1) |
|---|---|
| Revenue | $42,000 +163% from a year ago ($30,000 last quarter) |
| Medicaid births in covered states | ~140,000/yr Florida (~90k) and Illinois (~50k, priced at $525) |
| Cash and marketable securities | $72.8M $7.3M operating cash burn in Q3 |
⚖️ Verdict: 🟢 Bullish
The story got better because the state Medicaid strategy is now repeatable and carries a public price. Winning Florida adds 90,000 annual Medicaid births to Illinois's 50,000, and June's restructuring lowered research spending enough to fund a 25% larger sales team. The bad news: the company burned $7.3 million in cash this quarter, leaving about 10 quarters of funds at the current pace, and major private insurers are still discussing 2027 pilots rather than standard coverage.
The question now is whether Medicaid fee-schedule wins in Illinois and Florida turn into paid claims quickly enough to cut cash burn in 2027. Optimists see 140,000 covered Medicaid births and a $525 price anchor ready to drive revenue, while skeptics point to a year of pilot programs that produced only $42,000 in quarterly sales. Signed contracts with Illinois Medicaid managed care plans and first-quarter 2027 collections will tell.
🐂 Bull Case
Florida Doubles Medicaid Reach and Illinois Sets Pricing
Sera Prognostics sells PreTRM, a blood test that predicts the risk of premature birth between weeks 18 and 21 of pregnancy. Because private insurers rarely pay for new diagnostic tests right away, the Utah company has focused on winning state Medicaid coverage first.
That state strategy delivered two concrete wins this quarter. Florida added PreTRM to its Medicaid fee schedule, and Illinois published its payment rate while the company is in talks with a major insurer "regarding a large multi-state, multi-thousand-patient pilot with planned initiation in fiscal year 2027".
- Florida Medicaid: about 90,000 births a year and 4 million beneficiaries added
- Total Medicaid reach: about 7 million patients and 140,000 annual births across Illinois and Florida by our math
- Illinois Medicaid price: $525 per test with no prior approval required
- Partnership programs: 4 live programs after launching a state-based national payer initiative
The $525 Illinois rate is the first public price anchor for the test. By our math, if the diagnostic group reaches its 1% to 2% first-year target across Illinois's 50,000 Medicaid births, that single state would bring in $260,000 to $525,000 next year.
What to watch: signed contracts with the Medicaid managed care plans in Illinois and Florida over the next two quarters. State fee schedules set the price, but managed care contracts are required before doctors can bill for most Medicaid patients.
Restructuring Cut Research Costs to Fund Sales Hiring
In June, the diagnostics maker cut its staff to shift money from clinical trials into sales. Total operating expenses dropped 11% from last quarter to $8.9 million, though $0.4 million in new severance charges shows the overhaul is still wrapping up.
By our math, excluding severance from both quarters, underlying operating costs still fell 2.5% from the second quarter. Research and development spending dropped 17.1% from a year ago to $2.7 million, and general and administrative overhead fell 4.5% to $3.9 million.
Those savings paid for a 25% expansion of the sales force in the third quarter and more hires in early October for Florida. Selling and marketing expenses rose 41.5% from a year ago to $2.3 million without pushing total costs higher.
What to watch: first-quarter 2027 research and administrative expenses, when the company plans for cash costs in those departments to sit 35% and 25% below prior levels. Hitting those targets will show whether the cost structure can shrink while the sales team grows.
European Guidelines and Trial Data Back the Test
Doctors and insurers rarely adopt a new pregnancy screening test until medical societies endorse it and peer-reviewed journals publish the trial data. Following the January publication of its 5,018-patient PRIME study, the Salt Lake City company has kept publishing follow-up data.
This quarter, the European Association of Perinatal Medicine included PreTRM in its clinical guidelines "as a potential tool to support improved prediction of preterm birth risk". The group also started its European CE Mark regulatory submission for a kit-based version of the test.
In the United States, a published PRIME study analysis of first-time mothers showed the test cut neonatal intensive care admissions by 22%. First-time mothers have no prior pregnancy history to help doctors spot premature birth risk, making them the clearest clinical market for a blood test.
What to watch: completion of the full European CE Mark submission package in the fourth quarter and the announcement of a European commercial partner. Approval without a local distributor will not produce European sales.
🐻 Bear Case
Unpaid Tests Keep Sales Tiny Despite Volume Gains
"The third quarter marked an important step forward as we continued our transition from evidence generation to commercial execution," chief executive Zhenya Lindgardt said. She highlighted that PreTRM test volume rose 54% from the second quarter and almost five-fold from the first quarter, while ordering doctors grew 34% sequentially.
The income statement shows how little of that activity gets paid for today. Total revenue was $42,000, up $12,000 from the second quarter, and the cost of running the tests was $61,000, leaving a gross loss of $19,000.
Sera Prognostics said revenue suffered from lower average selling prices "due to a higher mix of low or non-reimbursed tests". Giving away or heavily discounting tests builds doctor awareness, but it does not prove that insurers or clinics will pay full price once pilot programs end.
What to watch: the average revenue collected per test once Illinois Medicaid managed care billing starts in early 2027. If test volume keeps rising while revenue stays under $100,000 a quarter, doctors are ordering the test only when it is free or subsidized.
Cash Burn Leaves Ten Quarters of Funds
Because the test brings in almost no cash yet, the business runs on the money it raised in early 2025. Cash and marketable securities ended September at $72.8 million, down $7.4 million from June after operating activities used $7.3 million in the third quarter.
In previous quarters, the company said its cash pile would fund operations through 2029. By our math, stretching $72.8 million across the 13 quarters left until the end of 2029 requires average quarterly cash burn to drop to $5.6 million, or 23% below this quarter's pace.
Shrinking cash balances also reduce the interest the company earns on its treasury portfolio. Other income, which is mostly interest, fell 28.4% from a year ago to $836,000, which pushed the quarterly net loss up 3.1% to $8.1 million even though operating expenses fell.
What to watch: quarterly operating cash burn in the first half of 2027, once severance payments end andFlorida sales hiring is in the run rate. Burn staying above $6 million a quarter would leave the company short of its 2029 target without issuing shares.
Risks this quarter didn't answer
Several standing concerns about adoption speed, disclosure and older pipeline plans received no new numbers in the third-quarter release.
- Exact test volume: the release gave percentage gains (+54% sequentially) without the actual number of tests run or the share that was paid.
- Total payer pipeline: the release did not update the count of active payer discussions, which stood at more than 20 last quarter.
- Commercial insurer coverage: talks with a large national insurer are for a multi-state pilot in 2027, showing that major private payers still want pilot studies before granting standard coverage.
- US medical guidelines: the release mentioned European guidelines, while a timeline for American College of Obstetricians and Gynecologists endorsement remains unstated.
- Older pipeline products: the Time to Birth consumer test and Predictive Analytics tool once planned for late 2025 went unmentioned for a seventh straight quarter.
👓 Other Themes
State Biomarker Laws Open a Public Coverage Path
Both of Sera Prognostics' Medicaid wins came from state laws requiring public health plans to cover biomarker blood tests. Florida's 2024 biomarker law and Illinois's June 2026 mandate placed PreTRM's billing code on state fee schedules, giving the company access to roughly 7 million Medicaid beneficiaries without waiting years for individual health plan medical reviews.
💲 Other KPIs
Deferred revenue — upfront cash collected from partner Elevance Health for tests not yet delivered — edged down by $47,000 over the first nine months of 2026, from $20.32 million at the end of 2025. The balance has sat near $20.3 million since 2024 because minimal test volume has been billed against the prepayment.
Diluted share count rose 2.6% from a year ago and 0.6% from the second quarter. The pregnancy diagnostics maker raised no money from stock offerings during the first nine months of 2026, so the small increase came entirely from employee stock options and stock purchase plans.
🔮 Guidance
Unchanged. The company started its regulatory submission process with its European reviewer for the kit-based PreTRM Global test during the third quarter, matching the schedule it set in August. That timeline had previously slipped three times, moving from early 2026 to mid-year and then to the second half of 2026.
❓ Key Questions
How many tests did doctors order, and how many paid?
Management reported a 54% sequential jump in test volume and a five-fold increase since the first quarter, but revenue grew by only $12,000. Without the actual test count and the share of unpaid tests, investors cannot judge real commercial demand.
What is the Medicaid payment rate on Florida's fee schedule?
The release disclosed a $525 rate for Illinois Medicaid but did not state the dollar rate on Florida's laboratory fee schedule. Because Florida has 90,000 annual Medicaid births — almost double Illinois — its price determines the size of the 2027 revenue opportunity.
Did the count of active payer discussions grow this quarter?
Last quarter the company highlighted discussions across more than 20 payer opportunities in over 20 states. The third-quarter release did not give an updated count, leaving it unclear whether the pipeline of health plans is still expanding or shifting into pilots.
When will the $20.3 million Elevance prepayment turn into revenue?
Deferred revenue from the Elevance Health minimum-purchase agreement declined by only $47,000 over nine months. Management has not explained whether the new multi-state commercial pilot talks involve Elevance or when test volume under that contract will pick up.